Share This Article:

Evaluation of Surgical Outcome after Resection of Pancreatic Tumors, Our Experience in Mansoura Oncology Center, a Middle-Volume Center in Egypt

Abstract Full-Text HTML XML Download Download as PDF (Size:292KB) PP. 477-481
DOI: 10.4236/jct.2012.35061    3,605 Downloads   5,211 Views  

ABSTRACT

Background: Pancreatic cancer is the fourth most common cause of cancer related deaths in the world. Surgical resection remains the only potentially curative treatment for adenocarcinoma of the pancreas; only 10% - 20% of patients are candidate for standard pancreatic resection. Objective: To evaluate perioperative mortality, morbidity and survival for patients underwent PD in middle-volume center. Patients and Methods: Sixty patients with pancreatic tumors were enrolled in this study for different surgical procedure according to type of tumors. Results: No early postoperative complications were observed in 60% of patients, whereas 40% of patients developed one or more complication, the median survival for this group was 12.3 months with standard deviation 3.8 months.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

N. Shams, M. Mosbah, M. Hegazy, O. Hussein, O. Farouk, S. Roshdy, M. Hafez, A. Khater and K. Wahab, "Evaluation of Surgical Outcome after Resection of Pancreatic Tumors, Our Experience in Mansoura Oncology Center, a Middle-Volume Center in Egypt," Journal of Cancer Therapy, Vol. 3 No. 5, 2012, pp. 477-481. doi: 10.4236/jct.2012.35061.

References

[1] J. M. Hernandez, S. M. Cowgill, S. Al-Saadi, A. Collins, S. B. Ross, J. Cooper, et al., “CA 19-9 Velocity Predicts Disease-Free Survival and Overall Survival after Pancreatectomy of Curative Intent,” Journal of Gastrointestinal Surgery, Vol. 13, No. 2, 2009, pp. 349-353. doi:10.1007/s11605-008-0696-3
[2] S. M. Russo, R. Ove and M. W. Saif, “Identification of Prognostic and Predictive Markers in Pancreatic Adenocarcinoma. Highlights from the 2011 ASCO Gastrointestinal Cancers Symposium,” Journal of the Pancreas, Vol. 12, No. 2, 2011, pp. 92-95.
[3] C. J. Wray, S. A. Ahmad, J. B. Matthews and A. M. Lowy, “Surgery for Pancreatic Cancer: Recent Controversies and Current Practice,” Gastroenterology, Vol. 128, No. 6, 2005, pp. 1626-1641.doi:10.1053/j.gastro.2005.03.035
[4] C. Bassi, M. Falconi, R. Salvia, G. Mascetta, E. Molinari and P. Pederzoli, “Management of Complications after Pancreaticoduodenectomy in a High Volume Centre: Results on 150 Consecutive Patients,” Digestive Surgery, Vol. 18, No. 6, 2001, pp. 453-457.doi:10.1159/000050193
[5] American Cancer Society, “Global Cancer Facts and Fig- ures [Database on the Internet],” American Cancer Society, Atlanta, 2002.
[6] A. M. Kriegel, A. S. Soliman, Q. Zhang, N. El-Ghawalby, F. Ezzat, A. Soultan, et al., “Serum Cadmium Levels in Pancreatic Cancer Patients from the East Nile Delta Region of Egypt,” Environmental Health Perspectives, Vol. 114, No. 1, 2006, pp. 113-119.
[7] S. Nagai, T. Fujii, Y. Kodera, M. Kanda, T. T. Sahin, A. Kanzaki, et al., “Impact of Operative Blood Loss on Survival in Invasive Ductal Adenocarcinoma of the Pancreas,” Pancreas, Vol. 40, No. 1, 2011, pp. 3-9. doi:10.1097/MPA.0b013e3181f7147a
[8] C. J. Yeo, “Management of Complications Following Pancreaticoduodenectomy,” Surgical Clinics of North America, Vol. 75, No. 5, 1995, pp. 913-924.
[9] L. Capussotti, P. Massucco, D. Ribero, L. Vigano, A. Muratore and M. Calgaro, “Extended Lymphadenectomy and Vein Resection for Pancreatic Head Cancer: Out- comes and Implications for Therapy,” Archives of Surgery, Vol. 138, No. 12, 2003, pp. 1316-1322. doi:10.1001/archsurg.138.12.1316
[10] M. Niedergethmann, M. Farag Soliman and S. Post, “Postoperative Complications of Pancreatic Cancer Surgery,” Minerva Chirurgica, Vol. 59, No. 2, 2004, pp. 175-183.
[11] X. Dong, B. Zhang, M. X.Kang, Y. Chen, Q. Q. Guo and Y. L. Wu, “Analysis of Pancreatic Fistula According to the International Study Group on Pancreatic Fistula Classification Scheme for 294 Patients Who Underwent Pancreaticoduodenectomy in a Single Center,” Pancreas, Vol. 40, No. 2, 2011, pp. 222-228. doi:10.1097/MPA.0b013e3181f82f3c
[12] C. G. Yeo, “Whipple Procedure: 1935 to Present,” In: Douglas Evans PPaJA, Ed., Pancreatic Cancer 2002, pp. 125-137.
[13] J. D. Birkmeyer, A. L Warshaw, S. R Finlayson, M. R. Grove and A. N. Tosteson, “Relationship between Hospital Volume and Late Survival after Pancreaticoduodenectomy,” Surgery, Vol. 126, No. 2, 1999, pp. 178-183. doi:10.1016/S0039-6060(99)70152-2
[14] A. C. Berger, J. C. Watson, E. A. Ross and J. P. Hoffman, “The Metastatic/Examined Lymph Node Ratio is an Important Prognostic Factor after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma,” The American surgeon, Vol. 70, No. 3, 2004, pp. 235-240.
[15] M. Hellan, C. L. Sun, A. Artinyan, P. Mojica-Manosa, S. Bhatia, J. D. Ellenhorn, et al., “The Impact of Lymph Node Number on Survival in Patients with Lymph Node-Negative Pancreatic Cancer,” Pancreas, Vol. 37, No. 1, 2008, pp. 19-24. doi:10.1097/MPA.0b013e31816074c9
[16] T. M. Pawlik, A. L. Gleisner, J. L. Cameron, J. M. Winter, L. Assumpcao, K. D. Lillemoe, et al., “Prognostic Relevance of Lymph Node Ratio Following Pancreaticoduodenectomy for Pancreatic Cancer,” Surgery, Vol. 141, No. 5, 2007, pp. 610-618. doi:10.1016/j.surg.2006.12.013
[17] T. Zacharias, D. Jaeck, E. Oussoultzoglou, A. Neuville and P. Bachellier, “Impact of Lymph Node Involvement on Long-Term Survival after R0 Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas,” Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract, Vol. 11, No. 3, 2007, pp. 350-356. doi:10.1007/s11605-007-0113-3
[18] M. Adham, D. Jaeck, J. Le Borgne, E. Oussoultzouglou, M. P. Chenard-Neu, J. F. Mosnier, et al., “Long-Term Survival (5-20 Years) after Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Series of 30 Patients Collected from 3 Institutions,” Pancreas, Vol. 37, No. 4, 2008, pp. 352-357. doi:10.1097/MPA.0b013e31818166d2
[19] K. Tobita, H. Kijima, S. Dowaki, Y. Oida, H. Kashiwagi, M. Ishii, et al., “Thrombospondin-1 Expression as a Prognostic Predictor of Pancreatic Ductal Carcinoma,” Inter- national Journal of Oncology, Vol. 21, No. 6, 2002, pp. 1189-1195.
[20] G. Peros, G. A. Giannopoulos, S. Christodoulou, G. Konstantoudakis, K. Petropoulou and G. H. Sakorafas, “Good Results after Major Pancreatic Resections in a Middle-Volume Center,” Pancreas, Vol. 39, No. 3, 2010, pp. 411-414. doi:10.1097/MPA.0b013e3181bd94ce
[21] P. J. Lakhey, R. S. Bhandari, B. Ghimire and M. Khakurel, “Perioperative Outcomes of Pancreaticoduodenectomy: Nepalese Experience,” World Journal of Surgery, Vol. 34, No. 8, 2010, pp. 1916-1921. doi:10.1007/s00268-010-0589-y
[22] G. A. Gooiker, L. G. van der Geest, M. W. Wouters, M. Vonk, T. M. Karsten, R. A. Tollenaar, et al., “Quality Improvement of Pancreatic Surgery by Centralization in the Western Part of the Netherlands,” Annals of Surgical Oncology, Vol. 18, No. 7, 2011, pp. 1821-1829. doi:10.1245/s10434-010-1511-4
[23] R. Pezzilli, M. Falconi, A. Zerbi, R. Casadei, L. Valli, R. Varale, et al., “Clinical and Patient-Reported Outcomes after Pancreatoduodenectomy for Different Diseases: A Follow-Up Study,” Pancreas, Vol. 40, No. 6, 2011, pp. 938-945. doi:10.1097/MPA.0b013e318216f693

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.